Аннотация:
Blood pressure lowering by all classes of antihypertensive drugs is accompanied by significant reductions of stroke and major cardiovascular (CV) events. Drugs acting on the renin–angiotensin–aldosterone system, such as angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), showed similar benefit on major CV events to other antihypertensive medications. In real-world practice, ARBs reduced by 10[%] the incidence of CV mortality, non-fatal myocardial infarction, non-fatal stroke and provided superior protection against CV events than ACEIs in high-risk patients. Despite similar antihypertensive properties and a favourable safety profile for both ACEIs and ARBs, evidence indicates that patients treated with ARBs have lower rates of withdrawal for adverse events and greater persistence to therapy than those treated with ACEIs. Among ARBs, olmesartan is one of the latest generation compounds introduced in clinical practice for treating hypertension: head-t
Ключевые слова:
Ambulatory blood pressure; Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; Arterial hypertension; Blood pressure; Blood pressure variability; Cardiology; Olmesartan
angiotensin receptor antagonist; dipeptidyl carboxypeptidase inhibitor; olmesartan; angiotensin receptor antagonist; antihypertensive agent; calcium channel blocking agent; dipeptidyl carboxypeptidase inhibitor; imidazole derivative; olmesartan; tetrazole derivative; antihypertensive therapy; blood pressure variability; cardiovascular mortality; cardiovascular risk; cerebrovascular accident; clinical practice; combination drug therapy; comparative study; diabetes mellitus; drug safety; funding; heart infarction; human; hypertension; monotherapy; Review; hypertension; pathophysiology; renin angiotensin aldosterone system; treatment outcome; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Humans; Hypertension; Imidazoles; Renin-Angiotensin System; Tetrazoles; Treatment Outcome
Omboni S. Stefano 1963-
Volpe M.
Омбони С. Стефано 1963-
Волпе М.
Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan
Текст визуальный непосредственный
Advances in Therapy
Health Communications, Inc.
Vol.36, Issue2 P. 278-297
2019
Обзор
Ambulatory blood pressure Angiotensin converting enzyme inhibitors Angiotensin receptor blockers Arterial hypertension Blood pressure Blood pressure variability Cardiology Olmesartan
angiotensin receptor antagonist dipeptidyl carboxypeptidase inhibitor olmesartan angiotensin receptor antagonist antihypertensive agent calcium channel blocking agent dipeptidyl carboxypeptidase inhibitor imidazole derivative olmesartan tetrazole derivative antihypertensive therapy blood pressure variability cardiovascular mortality cardiovascular risk cerebrovascular accident clinical practice combination drug therapy comparative study diabetes mellitus drug safety funding heart infarction human hypertension monotherapy Review hypertension pathophysiology renin angiotensin aldosterone system treatment outcome Angiotensin Receptor Antagonists Angiotensin-Converting Enzyme Inhibitors Antihypertensive Agents Calcium Channel Blockers Humans Hypertension Imidazoles Renin-Angiotensin System Tetrazoles Treatment Outcome
Blood pressure lowering by all classes of antihypertensive drugs is accompanied by significant reductions of stroke and major cardiovascular (CV) events. Drugs acting on the renin–angiotensin–aldosterone system, such as angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), showed similar benefit on major CV events to other antihypertensive medications. In real-world practice, ARBs reduced by 10[%] the incidence of CV mortality, non-fatal myocardial infarction, non-fatal stroke and provided superior protection against CV events than ACEIs in high-risk patients. Despite similar antihypertensive properties and a favourable safety profile for both ACEIs and ARBs, evidence indicates that patients treated with ARBs have lower rates of withdrawal for adverse events and greater persistence to therapy than those treated with ACEIs. Among ARBs, olmesartan is one of the latest generation compounds introduced in clinical practice for treating hypertension: head-t